Breaking News, Collaborations & Alliances

Porton Advanced, Bennu Biotherapeutics Partner to Advance Cell Therapy R&D

Porton Advanced will provide CDMO services for multiple pipelines for gene and cell therapy, including plasmids, virus, TIL, TCR-T, and Treg

Suzhou Porton Advanced Solutions Ltd. entered into a strategic partnership with Bennu Biotherapeutics to advance cell and gene therapy R&D pipelines. The partnership aims to accelerate the development of T-cell therapies for tumors and autoimmune diseases. As an end-to-end gene and cell therapy service Contract Development and Manufacturing Organization (CDMO), Porton Advanced provides comprehensive services covering plasmids, cell therapy, gene therapy, oncolytic virus, mRNA therapy, and...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters